Targets › CCR9
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Receptor for chemokine SCYA25/TECK. Subsequently transduces a signal by increasing the intracellular calcium ions level..; FUNCTION: (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection. (UniProt, P51686)
Open in Phaseline: the race on CCR9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of Soochow University | CXCR4-enabled CCR9 chimeric antigen receptor T-cell injection CAR-T cells engineered to express chimeric antigen receptors targeting CXCR4 and CCR9 | CXCR4, CCR9 | Phase 1 | Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma | Dec 2026 |
| University College, London | CARCCR9 T cells anti-CCR9 CAR T cell therapy | CCR9 | Phase 1 | T Cell Acute Lymphoblastic Leukemia | Dec 2027 |
T Cell Acute Lymphoblastic Leukemia (1) Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma (1)
other (2)
University College, London (1) The First Affiliated Hospital of Soochow University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.